Citadel Advisors
CMMB

Citadel Advisors’s Chemomab Therapeutics CMMB Stock Holding History

Citadel Advisors’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$101K Sell
64,182
-39,599
-38% -$67.7K ﹤0.01% 12015
2025
Q4 		$171K Buy
+103,781
New +$275K ﹤0.01% 11178
2024
Q3 		– Sell
-15,601
Closed -$57.4K – 14330
2024
Q2 		$57.4K Buy
+15,601
New +$54K ﹤0.01% 11604
2024
Q1 		– Sell
-8,169
Closed -$16.7K – 14645
2023
Q4 		$16.7K Buy
+8,169
New +$21.5K ﹤0.01% 12782
2022
Q4 		– Sell
-5,307
Closed -$53K – 14911
2022
Q3 		$53K Buy
+5,307
New +$68.4K ﹤0.01% 11581
2021
Q1 		– Sell
-190
Closed -$21K – 13211
2020
Q4 		$21K Buy
+190
New +$18.3K ﹤0.01% 10771

Other funds holding CMMB

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
SP
SmartHarvest Portfolios Poulsbo, Washington $240M AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
PIP
Philadelphia Investment Partners Voorhees, New Jersey $147M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Citadel Advisors's CMMB Position: Q1 2026 in Review

Citadel Advisors reduced its Chemomab Therapeutics (CMMB) stake by 38% in Q1 2026, selling an estimated $67.7K and leaving 64,182 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #12015.

Citadel Advisors first reported a position in CMMB in Q4 2020 and has held it in 6 quarters since. The position peaked at $171K in Q4 2025. 15 funds tracked by Wall St. Rank hold CMMB as of Q1 2026.

  • Citadel Advisors held 64,182 shares of Chemomab Therapeutics worth $101K as of Q1 2026.
  • Citadel Advisors sold 39,599 Chemomab Therapeutics shares in Q1 2026, an estimated $67.7K.
  • Chemomab Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12015 holding.
  • Citadel Advisors first reported a position in Chemomab Therapeutics in Q4 2020 and has held it in 6 quarters since.
  • Citadel Advisors's Chemomab Therapeutics position peaked at $171K in Q4 2025.
  • 15 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.